Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/14539
Citations | ||
Scopus | Web of ScienceĀ® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Somogyi, A. | - |
dc.contributor.author | Bochner, F. | - |
dc.contributor.author | Hetzel, D. | - |
dc.contributor.author | Williams, D. | - |
dc.date.issued | 1995 | - |
dc.identifier.citation | Pharmaceutical Research, 1995; 12(1):149-154 | - |
dc.identifier.issn | 0724-8741 | - |
dc.identifier.issn | 1573-904X | - |
dc.identifier.uri | http://hdl.handle.net/2440/14539 | - |
dc.description.abstract | To determine the role of acid hydrolysis on the gastrointestinal absorption of erythromycin, six healthy subjects received erythromycin as a 240 mg intravenous dose, a 250 mg oral solution administered via endoscope directly into the duodenum and bypassing the stomach, and an enteric-coated 250 mg capsule. Blood samples were collected for 6 hours and serum erythromycin quantified by a microbiological method. The time to achieve maximum serum concentrations for the solution was 0.25 +/- 0.08 (mean +/- SD) hours and for the capsule was 2.92 +/- 0.55 hours. The absolute bioavailability of erythromycin from the capsule was 32 +/- 7% and for the duodenal solution 43 +/- 14%. The ratio of the areas under the serum erythromycin concentration-time curve of capsule to solution was 80 +/- 28% (range 38 to 110%). There is substantial loss of erythromycin apart from gastric acid hydrolysis, which cannot be accounted for by hepatic first-pass metabolism. Attempts to further improve the oral bioavailability of erythromycin beyond 50% by manipulation of formulation are likely to be futile. | - |
dc.language.iso | en | - |
dc.publisher | PLENUM PUBL CORP | - |
dc.source.uri | http://dx.doi.org/10.1023/a:1016215510223 | - |
dc.subject | Duodenum | - |
dc.subject | Humans | - |
dc.subject | Erythromycin | - |
dc.subject | Capsules | - |
dc.subject | Solutions | - |
dc.subject | Drug Administration Routes | - |
dc.subject | Administration, Oral | - |
dc.subject | Injections, Intravenous | - |
dc.subject | Biological Availability | - |
dc.subject | Intestinal Absorption | - |
dc.subject | Chemistry, Pharmaceutical | - |
dc.subject | Adult | - |
dc.subject | Female | - |
dc.subject | Male | - |
dc.subject | Evaluation Studies as Topic | - |
dc.title | Evaluation of the intestinal absorption of erythromycin in man: Absolute bioavailability and comparison with enteric coated erythromycin | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1023/A:1016215510223 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Somogyi, A. [0000-0003-4779-0380] | - |
Appears in Collections: | Aurora harvest 2 Pharmacology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.